A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.

被引：4
|
作者：
Ullenhag, Gustav J.
Yachnin, Jeffrey
Carneiro, Ana
Elison, Emma
Carlsson, Malin
Russell, Charlotte Astrid
Smith, Karin Enell
机构：
[1] Akad Sjukhus, Uppsala, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Lund Univ Hosp, Lund, Sweden
[4] Lund Univ, Lund, Sweden
[5] Alligator Biosci, Lund, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2646
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2646
引用
收藏
页数：2
相关论文
共 50 条
  • [21] NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.
    Voskoboynik, Mark
    Moser, Justin C.
    Lakhani, Nehal
    Millward, Michael
    Davar, Diwakar
    Harb, Wael A.
    Yang, Jing
    Means, Gary
    Manjarrez, Kristi
    Tercero, Almudena
    Zayed, Hany
    Hillson, Jan
    Dela Cruz, Christine
    Perez, Graciela
    Peng, Stanford L.
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Safety, tolerability, pharmacokinetics, and antitumor activity of FDA022-BB05 in patients with advanced/ metastatic solid tumors: A multicenter, open-label, first-in-human, phase I/Ib study
    Wang, X.
    Li, Y.
    Sun, J.
    Sun, Y.
    Li, H.
    Li, H.
    Wang, J.
    Ling, X.
    Yang, J.
    Yan, Y.
    Wang, X.
    Sun, W.
    Liu, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1420 - S1421
  • [23] A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors
    Dudek, Arkadiusz Z.
    O'Shaughnessy, Joyce
    Piha-Paul, Sarina A.
    Uprety, Dipesh
    Kitchens, Benjamin Lee
    Hutson, Thomas E.
    Rank, Brian H.
    Stokes, Michael
    Dudgeon, Crissy
    Surguladze, David
    Lightcap, Eric
    Drees, Jeremy
    Harrison, Ben
    Li, Richard
    LaCayo, Ashley
    Mattson, Paulette
    Bose, Nandita
    Karim, Dhamina
    Gargano, Michele Anne
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] CLINICAL UPDATE FROM A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL SINGLE AGENT STUDY OF SUPLEXA THERAPEUTIC CELLS IN PATIENTS WITH METASTATIC SOLID TUMOURS AND HAEMATOLOGIC MALIGNANCIES
    Joshi, Rohit
    Goh, Jeffrey
    Joubert, Warren
    Kwarta, Vineet
    Okera, Meena
    Bishnoi, Sarwan
    Lederer, Jim
    Borriello, Frank
    Gargosky, Sharron
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A663 - A663
  • [25] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
    Melero, Ignacio
    Tanos, Tamara
    Bustamante, Mariana
    Sanmamed, Miguel F.
    Calvo, Emiliano
    Moreno, Irene
    Moreno, Victor
    Hernandez, Tatiana
    Garcia, Maria Martinez
    Rodriguez-Vida, Alejo
    Tabernero, Josep
    Azaro, Analia
    Ponz-Sarvise, Mariano
    Spanggaard, Iben
    Rohrberg, Kristoffer
    Guarin, Ernesto
    Nuesch, Eveline
    Davydov, Iakov I.
    Ooi, Chiahuey
    Duarte, Jose
    Chesne, Evelyne
    McIntyre, Christine
    Ceppi, Maurizio
    Canamero, Marta
    Krieter, Oliver
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (695)
  • [27] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
    Krebs, Matthew
    Johnson, Melissa Lynne
    Cho, Byoung Chul
    Park, Keunchil
    Haddish-Berhane, Nahor
    Zemlickis, Donna
    Mitselos, Anna
    Meacle, Francis
    Knoblauch, Roland Elmar
    Hellemans, Peter
    Minchom, Anna Rachel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [29] Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies
    Ferrario, Cristiano
    Laurin, Julie
    Van Kempen, Leon
    Lambert, Caroline
    Spatz, Alan
    Markova, Oksana
    Batist, Gerald
    Langleben, Adrian
    Filion, Mario
    Jolivet, Jacques
    CANCER RESEARCH, 2017, 77
  • [30] A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.
    Boni, Valentina
    Garralda, Elena
    Colombo, Ilaria
    Homicsko, Krisztian
    Brana, Irene
    Gruber, Dorothea
    Fluckiger-Mangual, Stefanie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345